Enterprise Value
150.7M
Cash
96.52M
Avg Qtr Burn
-11.42M
Short % of Float
5.41%
Insider Ownership
20.83%
Institutional Own.
55.83%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Soticlestat (OV935) Details Dravet syndrome, Rare diseases, Rare genetic disease | Phase 3 Update | |
OV329 (GABA-AT inhibitor) Details Epilepsy | Phase 1 Data readout | |
OV101 (δ-selective GABAA receptor agonist) (gaboxadol) Details Genetic disorder, Rare genetic disease, Angelman Syndrome | Failed Discontinued | |
OV101 (gaboxadol) Details Rare genetic disease, Fragile X syndrome | Failed Discontinued | |
OV935 (CH24H Inhibitor) Details Rare diseases, Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, Rare genetic disease | Failed Discontinued |